Basilea Pharmaceutica - Incremental acquisition to arsenal; new guidance
Basilea has bolstered its drug pipeline with the in-licensing of fosmanogepix, a broad-spectrum antifungal candidate, from Amplyx Pharmaceuticals...
217 Views
Basilea Pharmaceutica - Growth pivot with potential antibacterial addition
Basilea has announced an exclusive evaluation licence and option agreement with South Korea-based iNtRON Biotechnology (KOSDAQ: 048530) for...
206 Views
Basilea Pharmaceutica - Antifungal addition to bolster pipeline
Basilea has announced an expansion of its portfolio to foster long-term growth, a key strategic priority for management, leveraging expertise in...
433 Views
Basilea Pharmaceutica - New data support FDA application for ceftobiprole
Basilea presented a combination of eight presentations and abstracts on its antibiotic ceftobiprole (at the Infectious Diseases Week 2023...
383 Views
Basilea Pharmaceutica - FDA accepts New Drug Application for ceftobiprole
Basilea has announced that the US FDA has accepted its New Drug Application (NDA) for ceftobiprole. The FDA has set a Prescription Drug User Fee...
244 Views